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Abstract: Interest in marine natural products has allowed the discovery of new drugs and 
trabectedin (ET-743, Yondelis), derived from the marine tunicate Ecteinascidia turbinata, was 
approved for clinical use in 2007. It binds to the DNA minor groove leading to interferences 
with the intracellular transcription pathways and DNA-repair proteins. In vitro antitumor 
activity was demonstrated against various cancer cell lines and soft tissue sarcoma cell lines. In 
phase I studies tumor responses were observed also in osteosarcomas and different soft tissue 
sarcoma subtypes. The most common toxicities were myelosuppression and transient elevation 
of liver function tests, which could be reduced by dexamethasone premedication. The efficacy 
of trabectedin was established in three phase II studies where it was administered at 1.5 mg/m2 
as a 24 h intravenous infusion repeated every three weeks, in previously treated patients. The 
objective response rate was 3.7%–8.3% and the tumor control rate (which included complete 
response, partial response and stable disease) was obtained in half of patients for a median over-
all survival reaching 12 months. In nonpretreated patients the overall response rate was 17%. 
Twenty-four percent of patients were without progression at six months. The median overall 
survival was almost 16 months with 72% surviving at one year. Predictive factors of response 
are being explored to identify patients who are most likely to respond to trabectedin. Combina-
tion with other agents are currently studied with promising results. In summary trabectedin is 
an active new chemotherapeutic agents that has demonstrated its role in the armamentarium of 
treatments for patients with sarcomas.
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Soft tissue sarcomas
Soft-tissue sarcomas are a highly heterogeneous group of tumors with a low incidence. 
They account for 1% of all adult and 15% of pediatric malignancies.1,2 At least 
50 different subtypes are distinguished, each with its specific biology and clinical 
outcome. The majority of these tumors are presumably derived from mesoderm and 
categorized by the normal tissue they resemble. As they are uncommon, however, 
they are subsumed under the collective term “soft-tissue sarcoma” and therapeutically 
approached in similar ways.
Despite adequate local treatment, up to one half of patients develop distant 
metastases. Most of these patients with advanced (ie, not resectable) or metastatic 
disease die from the disease after a median survival time from diagnosis ranging 
between eight to 12 months.3 The most common approach in all histological subtypes 
is to use doxorubicin and ifosfamide.4 Doxorubicin remains the reference in first line 
therapy with response rate of 20%–30% in large randomized trials.4–6 As a monotherapy, 
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ifosfamide yielded response rate similar to doxorubicin.5–8 
It is widely used as second-line therapy after anthracycline 
failure with a response rate in the 10%–20% range.8,9
Combining these agents might be more effective but has 
not been shown to improve survival in a significant way com-
pared to their use as single agents.6 Following suggestions 
that these agents may have a dose-response relationship,9–11 
various phase-I and -II trials were performed in which they 
were administered at high doses, yielding response rates of 
40%–66%12–15,16 leading to median overall survival of up to 
24 months in some studies. There are also suggestions that 
applying regimens with high response rates may render an 
initially inoperable tumor operable, thereby improving the 
outcome.17 But in two recent randomized trials,18–20 neither 
the response rate nor the overall survival could be improved 
by the intensification of chemotherapy, even if the progres-
sion-free survival was increased in one study.18
In recent years, progress has been made in understand-
ing the clinical and biological complexity of sarcomas,21,22 
such that oncologists have increasingly been able to define 
customized therapies. Paclitaxel has been found to be 
active mainly in patients with angiosarcomas.23 Docetaxel 
combined with gemcitabine has been shown to induce a 53% 
response rate in leiomyosarcomas of gynecological origin.24 
Topoisomerase inhibitors are active for rhabdomyosarco-
mas.25 And the identification of genetic abnormalities with 
the presence of fusion genes that are strongly associated 
with specific sarcoma subtypes has contributed towards 
understanding the biology of these tumors, and has facilitated 
their diagnosis. It has also opened new avenues for therapies 
targeted against the transcription pathways induced by these 
fusion proteins.26,27
In the past years, the interest in marine natural products has 
provided new possibilities of drug discovery.28 The first clinical 
agent derived from nucleosides obtained from marine sponge 
was cytosine arabinoside. Other marine compounds are in 
development such as aplidine obtained from the Mediterranean 
tunicate A. albicans or bryostatin from the bryozoan Bugula 
neritina. But trabectedin (ET-743, Ecteinascidin-743) is the 
first marine anticancer drug approved for clinical use in the 
European Union since 2007.
Trabectedin
Structure, mechanism of action, preclinical 
antitumor activity and phase i trials
Trabectedin (ET-743, Ecteinascidin, Yondelis) is a 
DNA-binding agent derived from the marine tunicate 
Ecteinascidia turbinata, now obtained by a semi-synthetic 
process starting with the antibiotic cynosafracin B.29,30 The 
molecule is comprised of three fused tetrahydroisoquinoline 
rings (Figure 1) of which two are covalently and reversibly 
bound to the DNA minor groove by a guanine specific alkyla-
tion at the N2 position. This induces a DNA bending towards 
the major groove.31,32 The third ring, being unbound, could 
interact with nuclear proteins. The transcriptional activation 
of inducible genes is inhibited, depending on the presence 
of the DNA repair systems, particularly the transcription 
coupled nucleotide excision repair system.33 The sensitiv-
ity to trabectedin is related to the presence of active repair 
mechanisms.34 A cell cycle arrest at G2/M and apoptosis is 
induced through a p53-independent process.35
In vitro, trabectedin has a broad spectrum of activity 
in human primary tumor cells.36 The drug was very active 
against several different sarcoma cell lines37 and the results 
of activity in human tumor xenografts demonstrated activ-
ity in melanoma, non-small cell lung cancer and ovarian 
cancer.38,39
Pharmacokinetics and phase i studies
After infusion, trabectedin is rapidly cleared from plasma, 
undergoing an extensive hepatic metabolism mainly through 
the cytochrome P450 3A4.40 Trabectedin has a high apparent 
volume of distribution and a half-life of approximately 
90 hours.41 It is mainly excreted in the feces but less than 1% 
is excreted unchanged in the urine or feces.42
In phase I studies (Table 1), different schedules were 
investigated in patients with solid tumors. This schedules 
range from an intravenous infusion over 1, 3, 24, or 72 hours 
every three weeks to a weekly infusion for three out of a 
four-week cycle.43–47 The dose-limiting toxicities (DLT) were 
mainly hematological (neutropenia, thrombocytopenia) and 
fatigue. Grade 3–4 hepatic toxicities were also DLT in some 
but not all trials.45,46 DLT were transient and not cumulative. 
Nausea and vomiting were managed with 5HT3-antagonists. 
Fatigue or asthenia grade 3–4 was also frequently described 
(8% to 50%). Tumors responses were observed in soft tissue 
sarcoma, osteosarcoma, melanoma, and breast cancer.
Two schedules were recommended for further phase II 
studies: 1.5 mg/m2 as a 24-hour continuous infusion given 
every three weeks and 0.58 mg/m2 as a three-hour infusion 
given weekly for three out of four weeks.
Phase ii studies of trabectedin  
in pretreated sarcomas
The efficacy of trabectedin was studied in four phase-II 
studies in pretreated soft tissue sarcoma from US and 
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Europe48–50 of which one was a randomized phase II study 
comparing two different schedules51 (Table 2).
The first trial, published in 2004 by Yovine and 
colleagues,48 investigated trabectedin 1.5 mg/m2 adminis-
tered as a 24-hour continuous infusion. Fifty-four patients 
were enrolled and analyzed in two predefined groups. The 
first group of 26 patients was pretreated with only one or 
two single agents or one combination regimen and the 
second group of 28 patients were heavily pretreated with 
at least three chemotherapeutic agents or two combina-
tions. The predominant histology was leiomyosarcoma 
(n = 22, of uterine origin (n = 8)), and liposarcoma (n = 6). 
Two partial responses (3.7% [95% confidence interval 
(CI): 0.5%–12.8%]) were reported and both had uterine 
leiomyosarcoma, four (7.4%) patients had a minor response, 
and nine (17%) patients had stable disease. Among the 
six responding patients, five received prior chemotherapy 
with ifosfamide and doxorubicin. The median progression-
free survival was 1.9 months after a median follow-up of 
26 months. At three and six months, 38.8% and 24.1% of 
patients were progression-free, respectively. No difference 
was noted in progression-free survival between the two 
groups. But the less pre-treated patients had a longer median 
overall survival of 13.7 months versus 7.9 months. Overall, 
the median survival was 12.8 months with 30% of patients 
alive at two years.
Garcia-Carbonero and colleagues reported the results of 
the phase II study with trabectedin 1.5 mg/m2 administered 
as a 24-hour continuous infusion, conducted in 36 patients 
pretreated with up to two prior chemotherapy regimens.50 
Some histological subtypes were excluded as gastrointes-
tinal stromal tumors (GIST), mesothelioma, osteosarcoma, 
carcinosarcoma, Kaposi’s sarcoma, or rhabdomyosarcoma. 
And the main histologies were leiomyosarcomas (n = 13), 
liposarcomas (n = 10), and synovial sarcomas (n = 6). One 
complete response (CR) was obtained in a patient with lipo-
sarcoma, and two partial responses (PR) in a patient with leio-
myosarcoma and in a patient with liposarcoma, for an overall 
response rate of 8% (95% CI: 2%–23%). Two other patients 
had a minor response. The median time to progression was 
1.7 months and the median overall survival was 12.1 months 
with an overall survival rate at one year of 53.1%.
The third study published by Le Cesne and colleagues49 
was conducted in eight European centers by the European 
Organisation for Research and Treatment of Cancer 
(EORTC) and administered trabectedin at 1.5 mg/m2 as a 
24-hour continuous infusion. One hundred and four patients 
were accrued with progressive soft tissue sarcomas excluding 
GIST. Most patients had leiomyosarcomas  (n = 43), synovial 
sarcomas (n = 18), or liposarcomas (n = 10). There were 
eight partial responses (in leiomyosarcomas [n = 5], synovial 
sarcoma [n = 1], liposarcoma [n = 1], and malignant fibrous 
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Figure 1 Structure of trabectedin.
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histiocytoma [n = 1]) and forty-five (40.5%) stable disease. 
Disease stabilization longer than six months was measured 
in 26% of patients. Of note the tumor control rate (defined as 
non progressing patients) reached 56% in leiomyosarcomas, 
61% in synovial sarcomas, and 40% in liposarcomas. After 
a median estimated follow-up of 34 months, the median 
time to progression was 3.4 months. The progression-free 
rates at 3, 6, and 12 months were respectively 52%, 29%, 
and 17%. GIST histology has been evaluated separately. 
Among 28 patients none responded and the best effect was 
disease stabilization in nine patients. The median time to 
progression was less than two months allowing to conclude 
that trabectedin was ineffective in GIST when given alone 
with this schedule.52
The results of these three phase II48–50 studies involv-
ing 183 patients were pooled and analyzed by Le Cesne.53 
Leiomyosarcoma remained the main histological subtype 
representing 41% of patients followed by liposarcoma in 
14% and synovial sarcoma in 11%. Most patients (95%) 
were pretreated with anthacyclines or ifosfamide and 113 
patients were resistant to anthracyclines, 81 resistant to 
ifosfamide, and 63 to both agents. The overall response rate 
was 7.7%. The clinical benefit, defined as the combination 
of the rate of objective response and of minor response and 
of stable disease, was 51.5%. The median overall survival 
was 10.3 months with an overall survival rate at one year of 
47.5% and a progression-free survival rate at six months of 
19.8%. The clinical benefit was similar in patients with bulky 
disease, with multiple pretreatments, with short previous 
progression-free survival or with early resistance to standard 
chemotherapy, suggesting the lack of cross resistance and a 
specific mechanism of action.54
Table 2 Efficacy and survival data of trabectedin in phase II trials
Reference Study type N Subtype  
of sarcoma
Overall response Disease control Median TTP 
(months)
Median OS 
(months)
Yovine48 Phase ii, second line 28 LMS/Lipo 2
3.7% 24% at six months 1.9 12.8
22 Other 0
Garcia-Carbonero50 Phase ii, second line 23 LMS/Lipo 3
8.3% ND 1.7 12.1
13 Other 0
Le Cesne49 Phase ii, second line 53 LMS/Lipo 6
8.1% 53.6% 3.5 9.3
51 Other 2
Pooled analysis Le 
Cesne AACr 200353
Phase ii, second line 183 7.7% 51.4% ND 10.3
Morgan ASCO 200751 Phase ii, second line 136 3-weekly 5.6 38.9% 3.7 13.8
134 weekly 1.6 24.3% 2.3 11.8
Garcia-Carbonero61 Phase II, first line 24 LMS/Lipo 4
17.1% 20% 1.6 15.8
12 Other 2
Abbreviations: ND, no data; LMS, leiomyosarcoma; Lipo, liposarcoma;  TTP, time to progression; OS, overall survival.
Table 1 Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) in Phase i studies
Reference Schedule N MTD DLT Recommended 
dose for phase II
ryan44 72 h infusion every 3 weeks 21 1.2 mg/m2 Transamanitis, rhabdomyolysis,  
neutropenia
1.05 mg/m2
Taamma45 24 h infusion every 3 weeks 52 1.8 mg/m2 Neutropenia, thrombocytopenia 1.5 mg/m2
Twelves46 1 h infusion every 3 weeks 40 1.1 mg/m2 Fatigue, neutropenia, thrombocytopenia 1 mg/m2
3 h infusion every 3 weeks 32 1.8 mg/m2 Fatigue, hyperbilirubinemia, 
thrombocytopenia.
1.65 mg/m2
villalona-Calero47 Daily for five days every  
3 weeks
42 0.325 mg/m2/d Neutropenia, thrombocytopenia 0.325 mg/m2/d
Farouzeh43 3 h infusion weekly for three 
weeks of a four week cycle
31 0.65 mg/m2 Neutropenia and hyperbilirubinemia 0.58 mg/m2 
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A phase II randomized trial was conducted in patients 
with liposarcoma or leiomyosarcoma after failure of anthra-
cyclines and ifosfamide.51 Two hundred seventy patients 
received either trabectedin at 0.58 mg/m2 as a 3 h weekly 
infusion, three out of four weeks or at 1.5 mg/m2 as a 24 h 
continuous infusion every three weeks. A significantly lon-
ger time to progression was achieved for the three weekly 
regimen reaching 3.7 months and 2.3 months for the weekly 
regimen (p = 0.0302, hazard ratio [HR]: 0.734). The median 
overall survival was 13.8 months for the three weekly and 
11.8 for the weekly regimen. The clinical benefit favored 
the three weekly regimen even if not statistically significant 
(58% versus 44%). Neutropenia grade 3–4 was described 
in 47% and 13% on the three weekly and the weekly arm, 
respectively, but it did not translate to a different rate of 
febrile neutropenia (0.8%). Similarly grade 3–4 transaminitis 
(ALAT) was more frequent in the three weekly arm (48% 
versus 9%), but without clinical consequences.
The results of the compassionate use programs in an 
unselected population, even though most of them included 
leiomyosarcomas or liposarcomas, were very similar in term 
of efficacy and toxicity.55–59 And in a historical comparison, 
progression-free survival of trabectedin was better than the 
other active chemotherapeutic agents.60
First line trabectedin in sarcomas
A phase II trial from Garcia-Carbonero and colleagues 
evaluated 36 patients with advanced or metastatic soft 
tissue sarcomas.61 The main histological subtypes were 
leiomyosarcomas (n = 15) and liposarcomas (n = 9). 
One complete response and five partial responses were 
observed for an overall response rate of 17.1% (95% 
CI: 6.6%–33.6%). Responses occurred in three patients 
with liposarcoma, and one patient each with leiomyosar-
coma, synovial sarcoma, and fibrosarcoma. One patient 
with a uterine leiomyosarcoma had a minor response. 
The median progression-free survival was 1.6 months and 
the progression-free rate at 6 months was 24.4%. Median 
overall survival was 15.8 months and overall survival at 
one year was 72%.
Tolerability
The toxicity profile encountered in the phase II trials was 
similar to the results observed in the phase I studies evalu-
ating the 24-hour continuous infusion of trabectedin at the 
recommended dose. Myelosuppression and hepatic toxicity 
were the most frequently observed adverse events (Table 3). 
Despite neutropenia grade 3–4 in 33%–61% of patients, there 
was a low incidence of febrile neutropenia (6%–7%), quite 
different from other agents as doxorubicin (up to 19%)18,62 
or ifosfamide regimens (up to 39%).5,8,9 Thrombocytopenia 
and anemia grade 3–4 was seen in 9%–22% of pretreated 
patients, but not in first line therapy.
Liver toxicity was frequent, but not cumulative and 
rapidly reversible. Transaminase elevation at more than 
five times the normal range was described in 20% to 57% 
of pretreated and 30% of the nonpretreated patients. This 
toxicity could be improved by dexamethasone premedication. 
In xenografts models, the hepatotoxicity induced by trabect-
edin was markedly reduced or avoided after administration 
of metabolism modulators such as dexamethasone or 
beta-naphtoflavone 24 h before trabectedin.63 The authors 
reported no difference in antitumor efficacy and hypothesized 
a decreased hepatic exposure to trabectedin, perhaps by regu-
lation of hepatic metabolism.64 In the clinic dexamethasone 
premedication was retrospectively analyzed by Grosso and 
colleagues.55 Twenty-three patients treated with trabectedin 
1.0 to 1.65 mg/m2 as a three-hour or 24-hour continu-
ous infusion every 21 days did not receive premedication 
whereas 31 patients received dexamethasone 4 mg per os 
Table 3 incidence of grade 3/4 toxicities in phase ii trials
Reference N Neutropenia Febrile 
neutropenia
Thrombocy-
topenia
Transaminitis Nausea Asthenia/
fatigue
Yovine48 Phase ii,  
second line
54 33 (61%) 4 (7%) 10 (19%) 26 (48%) ASAT 
31 (57 %) ALAT
4 (7%) 8 (15%)
Garcia-Carbonero50 Phase ii,  
second line
36 12 (34%) 2 (6%) 6 (17%) 9 (26%) ASAT 
7 (20%) ALAT
2 (6%) 0
Le Cesne49 Phase ii,  
second line
104 52 (52.5%) 9 (9.1%) 18 (18.2%) 35 (35.3%) ASAT 
44 (44.5%) ALAT
7 (7.1%) 0
Garcia-Carbonero61 Phase ii,  
first line
36 12 (33%) 0 0 12 (34%) ASAT 
13 (36%) ALAT
5 (14%) 4 (11%)
Abbreviations:  ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase.
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bid 24 hours before therapy. The incidence of grade 3–4 
transaminitis was reduced from 70% to 3% of patients by the 
dexamethasone premedication. The incidence of neutropenia 
and thrombocytopenia was also less important at 10% and 0% 
instead of 39% and 35%, respectively. The antitumor activity 
was similar between the two groups and comparable to the 
ones reported in other phase II trials. The overall response 
rate was 9% and the median progression-free survival was 
2.6 months.
The analysis of four treatment-related deaths in the 
European phase II study49 revealed a statistical correlation 
between these severe toxicities and liver dysfunction. The 
influence of patient characteristics and pathophysiological 
variables was analyzed in 69 patients treated in phase II 
studies.65 The incidence of severe toxicity was significantly 
(p = 0.02) greater for patients with any baseline liver function 
test exceeding the upper limit of the normal range. Thus the 
administration of the full dose of trabectedin at 1.5 mg/m2 
requires normal alkaline phosphatase and transaminase 
levels, checked before each cycle, and the dose should be 
reduced to 1.2 mg/m2 in case of abnormal bilirubin level, and 
more than 2.5 increase of transaminase or alkalin phosphatase 
above the normal range.
Other frequent toxicities included nausea, vomiting and 
fatigue that could be grade 3–4 in up to 9% of patients. 
Elevation of creatine phosphokinase (CK) has been 
reported in 26% of patients and a few cases of severe and 
fatal rhabdomyolysis have been observed in the phase I–II 
studies.44,48,66 By an unknown mechanism, trabectedin induced 
necrosis of skeletal muscle resulting in subsequent release of 
intracellular contents leading to electrolyte imbalance, renal 
failure and death. Caution should be taken when used with 
other medications known to cause muscle injury as statins. 
CK is the most sensitive indicator of muscle injury and should 
be 2.5× upper limit of normal before each treatment and 
closely monitored during therapy.
Perspective
Predictive factors of response
The mechanism of action of trabectedin is not well under-
stood, but it acts partially through interferences with the 
transcription pathways.67–69 The sensitivity of myxoid 
liposarcoma carrying a specific chromosomal translocation 
t(12; 16)(q13; p11) or t(12; 22)(q13; q12) that produce a 
DDIT3-FUS (DDIT3-EWSR1) fusion protein has been 
clinically recognized.62 Under treatment, the tissue density 
changes were consistent with a decrease in cellularity before 
tumor shrinkage, suggesting that it has modulated adipocyte 
differentiation. Recent in vivo data confirmed that trabectedin 
was able to induce a cascade of events leading to the activa-
tion of adipogenesis differentiation in cell lines presenting 
similar fusion genes.70 It opens interesting perspectives for 
the treatment of other translocation-related sarcomas and for 
the combination with other differentiating agents.
Trabectedin promotes DNA damage through its binding 
to N2 guanine in the minor groove causing a structural 
bending of DNA towards the major groove, and an 
unusual DNA helix distortion. This lesion is a substrate 
for the nucleotide excision repair (NER) pathway. In 
experimental models deficient cells in NER are insensitive 
to trabectedin.71 Thus the mRNA levels expression of 
ERCC1 (NER machinery), XPD (NER machinery), 
BRCA1 and BRCA2 were analyzed in 92 sarcoma patients 
by Schoeffski and colleagues.72 The six-month progression-
free survival and median overall survival were improved 
for patients with high expression levels of ERCC1 (32% 
versus 15% and 12 months versus seven months, respec-
tively). An increased six-month progression-free rate (33% 
versus 11%) and a longer median overall survival (15 
versus five months) were significantly associated with low 
expression of BRCA1. No significant effect of XPD and 
BRCA2 was found on progression-free survival and overall 
survival. Some patients were highly sensitive to treatment 
when a high ERCC1 and a low BRCA1 expression were 
measured. They had a six-month progression-free survival 
of 50% and a median overall survival of 20.4 months. If 
the treatment of sarcomas by trabectedin should be based 
on a specific repair mechanism profile remains to be shown 
in a prospective study.
Combinations
Combination treatments with doxorubicin,73 irinotecan,74 
and paclitaxel75 were evaluated in preclinical studies 
showing synergistic effects against sarcomas. Trabectedin 
was combined with doxorubicin,76,77 pegylated liposomal 
doxorubicin,77 paclitaxel,78 and capecitabine79 in phase I 
studies involving patients with solid tumors. The DLT were 
essentially myelosuppression and hepatotoxicity.
In sarcomas a phase I study combining doxorubicin and 
trabectedin reported that the maximum tolerated dose was 
60 mg/m2 and 1.1 mg/m2 respectively. Preliminary pharma-
cokinetics of both agents were not significantly modified 
by the combination. Because of severe neutropenia at the 
first dose level, granulocyte colony-stimulating factor had 
to be added subsequently. The dose limiting toxicities were 
neutropenia and thrombopenia. Dose reduction was required 
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in 51% of patients for trabectedin and 27% for doxorubicin. 
Among the 41 treated patients, five achieved a partial remis-
sion and 34 had a disease stabilization that lasted more than 
six months in 15 patients.77
Conclusion
The marine-derived DNA-binding protein trabectedin 
induces DNA damage and transcriptional interference, 
which are dependent on the presence of DNA-repair 
systems. In phase I studies, the optimal dose and sched-
ule of administration of trabectedin was 1.5 mg/m2 as a 
24 h intravenous continuous infusion every three weeks. 
In pretreated patients, the three phase II studies involving 
183 patients showed response rate up to 10% with disease 
control achieved in approximately 50% and a median overall 
survival of one year. Significant activity was also found in 
first line therapy with a response rate of 17% and 72% of 
patients surviving at one year. The treatment is generally 
well tolerated at the recommended dose. The most frequent 
severe toxicities were neutropenia, thrombocytopenia, and 
transient increase of hepatic tests. These adverse events were 
not cumulative and were rapidly reversible. Dexamethasone 
premedication reduced the hepatotoxicity and the myelosup-
pression. A better understanding of the mechanisms of action 
of trabectedin and its effect on transcription pathways make 
it a good candidate for combination with other chemothera-
peutic agents or targeted therapy.
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